AMG 232

DRUG3 trials

Sponsors

Kartos Therapeutics, Inc.

Conditions

Acute Myeloid LeukemiaAdvanced MalignancyAdvanced Solid TumorsCancerGlioblastomaMelanomaMultiple MyelomaOncology

Phase 1

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

CompletedNCT01723020

Kartos Therapeutics, Inc.Advanced Malignancy, Advanced Solid Tumors, Cancer +5

Start: 2012-12-27End: 2017-09-25Updated: 2021-09-02

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

CompletedNCT02016729

Kartos Therapeutics, Inc.Acute Myeloid Leukemia, Advanced Malignancy, Cancer +2

Start: 2014-04-01End: 2017-07-31Updated: 2019-02-27

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

CompletedNCT02110355

Kartos Therapeutics, Inc.Advanced Malignancy, Advanced Solid Tumors, Cancer +4

Start: 2014-12-19End: 2018-12-27Updated: 2021-03-26

Related Papers

Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia

Blood2019-11-133 citations

Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Blood2019-11-131 citations

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Blood Advances2019-06-2895 citations

Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with <i>TP53</i> wild type (TP53WT) metastatic cutaneous melanoma (MCM).

Journal of Clinical Oncology2017-05-2011 citations

Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Journal of Clinical Oncology2017-05-207 citations